Skip to content

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

Menu

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

November 2021

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Portfolio News / By Karina Tin

November 24, 2021

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Portfolio News / By Karina Tin

November 15, 2021

Surrozen Reports Third Quarter 2021 Financial Results

Portfolio News / By Karina Tin

November 15, 2021

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

Portfolio News / By Karina Tin

November 12, 2021

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

Portfolio News / By Karina Tin

November 12, 2021

A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021

Portfolio News / By Karina Tin

November 12, 2021

RAPT Therapeutics Reports Third Quarter 2021 Financial Results

Portfolio News / By Karina Tin

November 10, 2021

Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Portfolio News / By Karina Tin

November 10, 2021

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

Portfolio News / By Karina Tin

November 10, 2021

eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Portfolio News / By Karina Tin

November 8, 2021

Posts navigation

1 2 Next Page →

Search for:

Recent Posts

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
Eikon Therapeutics Announces Business Update Highlighting Pipeline and Clinical Development Progress ‍
Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics
Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746
RAPT Therapeutics Reports Second Quarter 2023 Financial Results

Recent Comments

Archives

Categories

Portfolio News
TCG News

The Column Group

Copyright © 2022. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications

Scroll to Top